Department of Laboratory Medicine, Konkuk University, Seoul, Korea.
Clin Chem. 2012 Dec;58(12):1703-10. doi: 10.1373/clinchem.2012.186569. Epub 2012 Oct 11.
Testosterone measurements that are accurate, reliable, and comparable across methodologies are crucial to improving public health. Current US Food and Drug Administration-cleared testosterone assays have important limitations. We sought to develop assay performance requirements on the basis of biological variation that allow physiologic changes to be distinguished from assay analytical errors.
From literature review, the technical advisory subcommittee of the Partnership for the Accurate Testing of Hormones compiled a database of articles regarding analytical and biological variability of testosterone. These data, mostly from direct immunoassay-based methodologies, were used to specify analytical performance goals derived from within- and between-person variability of testosterone.
The allowable limits of desirable imprecision and bias on the basis of currently available biological variation data were 5.3% and 6.4%, respectively. The total error goal was 16.7%. From recent College of American Pathologists proficiency survey data, most currently available testosterone assays missed these analytical performance goals by wide margins. Data from the recently established CDC Hormone Standardization program showed that although the overall mean bias of selected certified assays was within 6.4%, individual sample measurements could show large variability in terms of precision, bias, and total error.
Because accurate measurement of testosterone across a wide range of concentrations [approximately 2-2000 ng/dL (0.069-69.4 nmol/L)] is important, we recommend using available data on biological variation to calculate performance criteria across the full range of expected values. Additional studies should be conducted to obtain biological variation data on testosterone from women and children, and revisions should be made to the analytical goals for these patient populations.
准确、可靠且可跨方法比较的睾酮测量对于改善公共健康至关重要。目前美国食品和药物管理局批准的睾酮检测方法存在重要局限性。我们试图根据生物学变异制定检测性能要求,以区分生理变化和分析误差。
基于对激素准确检测的合作关系(Partnership for the Accurate Testing of Hormones)的技术顾问小组委员会从文献综述中汇编了有关睾酮分析和生物学变异性的文章数据库。这些数据主要来自基于直接免疫测定的方法,用于指定从个体内和个体间睾酮变异性中得出的分析性能目标。
根据目前可用的生物学变异数据,可接受的理想不精密度和偏差允许限值分别为 5.3%和 6.4%。总误差目标为 16.7%。根据最近的美国病理学家学院(College of American Pathologists)能力验证调查数据,大多数现有的睾酮检测方法远远未达到这些分析性能目标。最近成立的疾病预防控制中心(Centers for Disease Control and Prevention,CDC)激素标准化计划的数据显示,尽管选定的经认证检测方法的总体平均偏差在 6.4%以内,但个别样本测量结果在精密度、偏差和总误差方面可能存在很大差异。
由于准确测量广泛浓度范围内的睾酮(约 2-2000ng/dL[0.069-69.4nmol/L])非常重要,因此我们建议使用关于生物学变异的可用数据来计算整个预期值范围内的性能标准。应进行更多研究以获得来自女性和儿童的睾酮生物学变异数据,并应修订这些患者群体的分析目标。